Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2152W HIGH $1.17
Volume
202.47 K
Value Traded
43.15 K
Short % Float
2.14%
Days to Cover
3.9
-20.74%Week
-41.37%1 Month
-67.19%3 Month
-68.7%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
21.41 M
EPS (TTM)
-1.94
P/E Ratio
-
Ent. Value
-3.79 M
Total Shares
98.93 M
Float Shares
92.55 M
Insiders
6.51%
Institutions
35.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
DCGO Catalyst Timeline
Dated clinical, regulatory and corporate events for DocGo Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for DocGo Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How DCGO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
DocGo Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DCGO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bienstock LeeDirector, Officer (Chief Executive Officer) | Disposition | -15,644 2,801,826 held | $0.59 | 05/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DCGO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DCGO for Q2 2026. | ||||
Ownership Trends
DCGO Short Interest
Shares sold short, counted twice a month.
2.14%
Short % of Float
of tradable shares sold short
2.0M
Shares Sold Short
-0.8% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
504.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DCGO ranks across every disease it competes in
Competitive Position is a premium feature
See how DCGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDCGO News
-DCGO
Nov 3, 2026▲ +1.9%today
DocGo to Announce Third Quarter 2026 Results on Monday, November 9, 2026
DocGo announced it will release its third quarter 2026 results on November 9, 2026. The management will host a conference call and webcast at 5:00 p.m. ET on the same day. This event will provide insights into the company's financial performance for the quarter.
Read more →-DCGO
Sep 23, 2026DocGo Announces Upcoming Webinar to Outline Vision and Details of the Pending Hicuity Health Acquisition
DocGo Inc. has announced a webinar scheduled for September 29th, where CEO Lee Bienstock and Hicuity Health executives will discuss the details of DocGo's pending acquisition of Hicuity Health. This acquisition aims to enhance DocGo's offerings in tele-ICU and virtual care services, reflecting a strategic expansion in the mobile health sector.
Read more →-DCGO
Sep 1, 2026DocGo Announces Upcoming Participation at Morgan Stanley 24th Annual Global Healthcare Conference
DocGo Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. CEO Lee Bienstock will engage in 1x1 meetings and deliver a fireside presentation on September 16th at 12:20 PM ET. The event will also feature a webcast available on the company's investor relations page.
Read more →-DCGO
Aug 17, 2026▼ -33.1%on this news
DocGo Announces Second Quarter 2026 Results
DocGo Inc. reported its financial results for the second quarter of 2026, revealing a revenue decline to $73.4 million from $80.4 million in the same quarter of 2025. The decrease in revenue was entirely due to the cessation of migrant-related programs, impacting overall financial performance. The company continues to focus on its mobile health and medical transportation services.
Read more →-DCGO
Aug 10, 2026▼ -9.3%on this news
DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026
DocGo Inc. will announce its financial results for the second quarter of 2026 on August 17, 2026, after market close. The company will also host a conference call at 5:00 p.m. ET to discuss these results. This event highlights DocGo's commitment to keeping investors informed about its performance.
Read more →-DCGO
Jun 3, 2026▼ -8.4%on this news
DocGo Launches Mobile Phlebotomy Services in South Florida
DocGo has introduced mobile phlebotomy services in South Florida. This initiative aims to enhance patient convenience and accessibility to blood collection services. The launch reflects DocGo's commitment to expanding its healthcare offerings in the region. Further details on the operational aspects and expected impact were not provided.
Read more →-DCGO
May 26, 2026DocGo Announces Upcoming Participation at the Goldman Sachs 47th Annual Global Healthcare Conference
DocGo will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. The event is a significant opportunity for the company to engage with investors and discuss its strategic initiatives. Further details on the presentation and topics to be covered are yet to be announced.
Read more →-DCGO
May 11, 2026DocGo Announces First Quarter 2026 Results
DocGo has announced its financial results for the first quarter of 2026. However, the article does not provide specific details about the performance metrics or any significant developments during this period. The lack of detailed information limits the analysis of the company's current standing and future prospects.
Read more →-DCGO
May 11, 2026DocGo Announces First Quarter 2026 Results Company Increases 2026 Revenue Guidance Based on Strong Demand for Virtual Care Services
DocGo Inc. announced its first quarter results for 2026, highlighting a total revenue of $75.6 million, which reflects a steady growth excluding the wind-down of certain migrant-related programs. The company's revenue guidance for 2026 has been updated upward due to strong demand for virtual care services, with specific business lines reporting record volumes. However, the company is also facing challenges, showing an increase in net losses compared to the previous year. Management remains optimistic about future performance, expecting improvements in adjusted EBITDA as operational efficiencies are implemented.
Read more →-DCGO
May 6, 2026▼ -9%on this newsshared move
DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
DocGo Inc. announced its participation in the 21st Annual Needham Technology, Media, & Consumer Conference, where CEO Lee Bienstock will present. The event is scheduled for May 14, and a webcast will be available on their investor relations website. DocGo focuses on technology-enabled medical transportation and mobile health services.
Read more →-DCGO
Apr 27, 2026DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026
DocGo Inc. will announce its financial results for Q1 2026 on May 11, 2026, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results. The company focuses on technology-enabled medical transportation and mobile health services, aiming to enhance patient care and operational efficiencies.
Read more →-DCGO
Mar 16, 2026DocGo Announces Fourth Quarter and Full Year 2025 Results Company Raises 2026 Revenue and Adjusted EBITDA Guidance due to Customer Expansions, Improved EMS Hiring Rates and Efficiency Initiatives
DocGo Inc. has reported its financial results for the fourth quarter and full year of 2025, revealing a decline in total revenue primarily due to the end of migrant-related programs. The company raised its revenue and adjusted EBITDA guidance for 2026, anticipating growth driven by new expansions and efficiency initiatives. Despite a significant net loss and financial impairments in 2025, management remains optimistic about improving margins and profitability in the upcoming year, supported by their core healthcare services.
Read more →-DCGO
Nov 10, 2025DocGo Announces Third Quarter 2025 Results Company Achieves Record Volumes Across All Major Business Lines
DocGo Inc. reported its financial results for the third quarter of 2025, highlighting a significant decline in total revenue due to the winding down of migrant-related programs. Despite a decrease in overall revenue, the company announced record volumes across all major business lines, with particular growth in transportation services and mobile health. However, DocGo also faced a substantial net loss compared to the same quarter last year, which included non-cash impairments. Looking ahead, the company provided guidance for 2026, projecting increased revenues from its core services, excluding migrant-related programs.
Read more →-DCGO
Sep 30, 2025DocGo Acquires Virtual Care Platform SteadyMD, Expands Telehealth Services Across all 50 States
DocGo has announced its acquisition of SteadyMD, a virtual care platform, to enhance its telehealth services across all 50 states. This strategic acquisition aims to combine DocGo's mobile healthcare delivery with SteadyMD's virtual care capabilities, targeting a revenue generation of approximately $25 million in 2025. The integration is expected to streamline patient care delivery and access to healthcare services. Key officials from SteadyMD will join DocGo's leadership team to drive the combined operations forward.
Read more →-DCGO
Aug 7, 2025DocGo Announces Second Quarter 2025 Results
DocGo Inc. reported its second quarter 2025 financial results, indicating a decline in total revenue to $80.4 million compared to the previous year, largely due to the planned wind-down of migrant-related programs. Despite a net loss of $13.3 million, the company increased its cash balance to $128.7 million and continued to sign new contracts across various business sectors. Key corporate highlights included surpassing 1.2 million patients engaged for care gap closure services and launching new programs aimed at enhancing health service delivery. The company reaffirmed its revenue guidance for the full year 2025.
Read more →-DCGO
May 8, 2025DocGo Announces First Quarter 2025 Results Company Focuses on Growing Medical Transportation and Payer Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Ca
DocGo Inc. has reported its financial results for the first quarter of 2025, indicating significant challenges primarily due to municipal uncertainties and a strategic shift away from non-migrant government health services. Revenue decreased to $96.0 million from $192.1 million year-over-year, with an anticipated adjusted EBITDA loss of $20-$30 million. Despite this, the company achieved record medical transportation metrics and aims to grow through new partnerships and service expansions, while planning to reduce operational expenditures.
Read more →-DCGO
Feb 27, 2025DocGo Announces Fourth Quarter and Full-Year 2024 Results Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts
DocGo Inc. (DCGO) reported its financial results for the fourth quarter and full year of 2024, highlighting a revenue decrease primarily attributed to the wind-down of migrant-related programs. The company surpassed 700,000 patient lives in its care gap closure initiatives and expanded its contracts with healthcare partners. Despite these achievements, DocGo faced a net loss in Q4 2024 and lower adjusted EBITDA than anticipated, signaling challenges in transitioning from migrant services to core mobile health revenue. Management is optimistic about future growth and believes ongoing investments will drive the company's success moving forward.
Read more →-DCGO
Nov 7, 2024DocGo Announces Third Quarter 2024 Results Company Significantly Expands Operations on the West Coast to Support New Payer Programs, Increases Full-Year Guidance for Cash Flow from Operations Management to Host Conferenc
DocGo Inc. reported its third quarter 2024 financial results with notable changes. Total revenue decreased 26% due to the winding down of migrant-related programs, while net income showed a minimal decline. However, the company increased its full-year guidance for cash flow from operations and expanded its West Coast operations to support new payer programs. Key performance indicators, including adjusted EBITDA and cash flow, demonstrated positive trends despite the challenges faced in revenue from specific services.
Read more →-DCGO
Sep 30, 2024DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board
DocGo Inc. has appointed Dr. Stephen K. Klasko as the new independent, non-executive Chair of its Board of Directors, effective October 1, 2024. Dr. Klasko brings extensive experience in healthcare leadership, including roles at Thomas Jefferson University and Jefferson Health. His appointment is seen as a strategic move to enhance DocGo's mobile health services and value-based care strategies, with the company positioned for growth in the healthcare sector. Outgoing Chair Steven Katz will assist in the transition as a consultant.
Read more →-DCGO
Aug 7, 2024DocGo Announces Strong Second Quarter 2024 Results Company Raises Cash Flow From Operations Guidance to $80-$90 Million, Reiterates 2024 Revenue Guidance of $600-$650 Million and Adjusted EBITDA 1 Guidance of $65-$75 Mil
DocGo Inc. reported strong financial results for the second quarter of 2024, with a revenue increase of 31% year-over-year. The company raised its guidance for cash flow from operations to $80-$90 million and reaffirmed its revenue estimate for the year between $600-$650 million. Adjusted EBITDA also saw a significant rise, up 89% to $17.2 million. In addition, DocGo secured new contracts and expanded services, further positioning itself for growth in the mobile health sector.
Read more →About DocGo Inc.
Headquarters685 THIRD AVENUE, NEW YORK, NY, 10017
BIOPHARMAWATCH ELITE PLUS
Trade the next DCGO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime